Trump announces reforms to accelerate access to psychedelic drug treatments

Donald Trump announced reforms on Saturday aimed at accelerating access to psychedelic drug treatments, specifically directing the FDA to expedite the review of drugs like ibogaine. The executive order intends to pave the way for reclassification of these drugs, which can cause hallucinations and are largely illegal, after successful clinical trials. The US will also dedicate $50 million to federal research into ibogaine, which has shown potential in treating PTSD and substance abuse. The reforms could immediately benefit Texas, which has already invested in ibogaine research. The announcement was made with figures such as the US health secretary, Robert F Kennedy Jr, and Joe Rogan present, all of whom have expressed support for psychedelic research and/or legalization.

In April 2026, President Donald Trump signed an executive order directing his administration to expedite the review process for certain psychedelic drugs, including ibogaine. Ibogaine, derived from a West African shrub, has gained attention from veterans and lawmakers for its potential to treat conditions like PTSD and opioid addiction, despite safety concerns. While these drugs remain in the most restrictive category under federal law, the administration aims to ease restrictions and encourage research into their medical applications, such as severe depression. Trump stated the order would accelerate access to potential treatments, emphasizing the potential for significant impact if the drugs prove effective. The move follows pledges from administration officials to ease access to psychedelics for medical use, reflecting bipartisan support for the issue.

President Trump signed an executive order directing his administration to expedite the review process for certain psychedelic drugs, including ibogaine. Ibogaine, currently classified as a high-risk, illegal drug by the federal government, has gained recent attention for its potential benefits for combat veterans. The order aims to accelerate access to research and treatments involving these drugs, some of which have already been designated as potential breakthroughs by regulators. Trump stated the directive could offer relief to individuals suffering from debilitating symptoms and potentially improve their lives. The goal is to assess the potential benefits of these drugs and their impact on treatment options.